BOSTON PHARMA ACCOMPANY WITH 2023 AOAC SEA 2nd ANNUAL CONFERENCE

On 1 – 2 August 2023, Boston Pharma was accompanied 2023 AOAC SEA - 2nd Annual Conference organized by The AOAC Southeast Asia Section (AOAC SEA) and the Institute of Drug Quality Control in Ho Chi Minh City (IDQC-HCMC). The theme of the conference is “Facilitating Compliance for Food Safety and Quality in International Trade”.

The formation of the Southeast Asia section of AOAC International was approved by the AOAC Board of Directors. AOAC Southeast Asia (AOAC SEA) encompasses 10 countries: Vietnam, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, and Timor-Leste. The orientation of AOAC SAE is developing confidence in consensus-based analytical solutions for food safety, food integrity, and public health across Southeast Asia countries.

2023 AOAC SEA - 2nd Annual Conference has 200 delegates from ASEAN countries and 20 national and international speakers presenting current technical standards in quality control of packaging and materials according to international regulations (including AOAC, Codex…). The conference's goal is to connect and share information about technical standards for analysis of impurities in raw materials, packaging, and technique trends about harmonization of AOAC standards for manufacturing food and pharmaceutical production.

Boston Pharma accompany with 2023 AOAC SEA - 2nd Annual Conference

Representatives of Boston Pharma at 2023 AOAC SEA including Mr. Nguyen Tien Hung - Head of the QC Department and Mrs. Tran Thi Minh Huong - Head of the QC - EU Department participated with the aim to acquire knowledge and use it in concrete situations to optimize the production line and quality control.

Boston Pharma manufactures and distributes pharmaceutical and supplement products that have the same quality and safety as imported products in the European-American region. There are 11 treatment groups with over 250 different types of high-quality pharmaceuticals and supplement products. The company's production capacity is stable and growing, and it currently provides more than 1.4 billion product units per year.

Over the years, Boston Pharma also has a smart building monitoring and control system, automatic air conditioning (BMS), and machinery for the departments of research and development (R&D), quality assurance (QA), quality control, product quality, and a consistent drug production line.

Boston Pharma has optimal production technology and a modern equipment system

Nowadays, Boston Pharma has nine production lines continuously invested in modern technology with more than 340 pieces of equipment and machinery advanced from countries such as the USA, Italy, Germany, France, Japan, ... The company has a rich product ecosystem with the core value of focusing on quality to follow the mission of building healthy communities. We are committed to bringing the best quality pills.

Regarding Boston Pharma, we have modern equipment with talented HR who are very creative and dynamic from R&D Department. We usually cooperate with Universities and Testing Institutes to research new therapeutic drug groups, and product safety - quality that has positive effects on community health.